Loading…
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $124M | $-46M | $-39M | $-27M | -16.6% | 63.5% | - |
| 2024 | $76M | $-73M | $-73M | $38M | -32.6% | - | - |
| 2023 | $0M | $-137M | $-135M | $-63M | -75.5% | - | - |
| 2022 | $0M | $-109M | $-109M | $-105M | -40.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 75.62 | 123.67 |
| Operating Expense | 112.38 | 143.31 | 156.73 | 177.88 |
| Operating Income | -112.38 | -143.31 | -81.11 | -54.21 |
| EBITDA | -108.64 | -137.09 | -72.99 | -45.85 |
| EBIT | -112.38 | -143.31 | -81.11 | -54.21 |
| Pretax Income | -108.50 | -135.01 | -70.13 | -39.72 |
| Tax Provision | 0 | 0.34 | 2.57 | -1.10 |
| Net Income | -108.50 | -135.35 | -72.70 | -38.63 |
| Net Income Common Stockholders | -108.50 | -135.35 | -72.70 | -38.63 |
| Total Expenses | 112.38 | 143.31 | 156.73 | 177.88 |
| Interest Income | 3.76 | 9.33 | 10.57 | 12.94 |
| Research And Development | 85.06 | 111.27 | 121.56 | 141.50 |
| Selling General And Administration | 27.32 | 32.04 | 35.17 | 36.38 |
| Normalized EBITDA | -108.76 | -136.05 | -73.41 | -47.40 |
| Normalized Income | -108.62 | -134.53 | -73.03 | -40.13 |
| Basic EPS | -2.30 | -2.63 | -1.18 | 0 |
| Diluted EPS | -2.30 | -2.63 | -1.18 | 0 |
| Tax Effect Of Unusual Items | 0 | -0.22 | 0.09 | 0.04 |
| Tax Rate For Calcs | 0 | 0.21 | 0.21 | 0.03 |
| Total Unusual Items | 0.12 | -1.04 | 0.42 | 1.54 |
| Total Unusual Items Excluding Goodwill | 0.12 | -1.04 | 0.42 | 1.54 |
| Net Income From Continuing Operation Net Minority Interest | -108.50 | -135.35 | -72.70 | -38.63 |
| Reconciled Depreciation | 3.75 | 6.22 | 8.12 | 8.36 |
| Net Interest Income | 3.76 | 9.33 | 10.57 | 12.94 |
| Net Income From Continuing And Discontinued Operation | -108.50 | -135.35 | -72.70 | -38.63 |
| Total Operating Income As Reported | -112.38 | -143.31 | -81.11 | -54.21 |
| Diluted Average Shares | 47.23 | 51.40 | 61.51 | 0 |
| Basic Average Shares | 47.23 | 51.40 | 61.51 | 0 |
| Diluted NI Availto Com Stockholders | -108.50 | -135.35 | -72.70 | -38.63 |
| Net Income Including Noncontrolling Interests | -108.50 | -135.35 | -72.70 | -38.63 |
| Net Income Continuous Operations | -108.50 | -135.35 | -72.70 | -38.63 |
| Other Income Expense | 0.12 | -1.04 | 0.42 | 1.54 |
| Other Non Operating Income Expenses | 0 | 0 | 0 | 0 |
| Special Income Charges | 0.11 | 0.02 | 0 | 0.06 |
| Gain On Sale Of Ppe | 0.11 | 0.02 | 0 | 0.06 |
| Gain On Sale Of Security | 0.01 | -1.06 | 0.42 | 1.48 |
| Net Non Operating Interest Income Expense | 3.76 | 9.33 | 10.57 | 12.94 |
| Interest Income Non Operating | 3.76 | 9.33 | 10.57 | 12.94 |
| General And Administrative Expense | 27.32 | 32.04 | 35.17 | 36.38 |
| Other Gand A | 11.94 | 12.39 | 13.02 | 13.40 |
| Salaries And Wages | 15.39 | 19.65 | 22.15 | 22.98 |
| Operating Revenue | 0 | 0 | 75.62 | 123.67 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc.this co. | GLUE | - | - | - | -16.6% | - |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M |
| - |
| 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |